Last update 21 Nov 2024

HS-10370

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
KRAS G12C
Mechanism
KRAS G12C inhibitors(GTPase KRas G12C inhibitors)
Therapeutic Areas
NeoplasmsRespiratory Diseases
Active Indication
Advanced Malignant Solid NeoplasmKRAS G12C mutation Solid TumorsAdvanced Lung Non-Small Cell Carcinoma
Inactive Indication-
Originator Organization
Jiangsu Hansoh Pharmaceutical Co. Ltd.Jiangsu Hansoh Pharmaceutical Co. Ltd.
Active Organization
Jiangsu Hansoh Pharmaceutical Co. Ltd.Jiangsu Hansoh Pharmaceutical Co. Ltd.
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

4
Clinical Trials associated with HS-10370
NCT06594874 / Not yet recruitingPhase 1
A Phase Ib Study Evaluating the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
NCT05367778 / RecruitingPhase 1/2
A Phase 1/2, Open-label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-10370 Monotherapy in Patients with Advanced Solid Tumors
CTR20220710 / RecruitingPhase 1
HS-10370在晚期实体瘤患者中的安全性、耐受性、药代动力学和有效性的I/II期临床研究
[Translation] Phase I/II clinical study of the safety, tolerability, pharmacokinetics and efficacy of HS-10370 in patients with advanced solid tumors
100 Clinical Results associated with HS-10370
Login to view more data
100 Translational Medicine associated with HS-10370
Login to view more data
100 Patents (Medical) associated with HS-10370
Login to view more data
100 Deals associated with HS-10370
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
CN
Jiangsu Hansoh Pharmaceutical Co. Ltd.Jiangsu Hansoh Pharmaceutical Co. Ltd.
03 Jun 2022
KRAS G12C mutation Solid TumorsPhase 1
CN
Jiangsu Hansoh Pharmaceutical Co. Ltd.Jiangsu Hansoh Pharmaceutical Co. Ltd.
31 Oct 2024
Advanced Lung Non-Small Cell CarcinomaPhase 1
CN
Jiangsu Hansoh Pharmaceutical Co. Ltd.Jiangsu Hansoh Pharmaceutical Co. Ltd.
26 Aug 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05367778 (HS-10370-101, AACR2024)
ManualManual
Phase 1
KRAS G12C mutation Solid Tumors
55
(ybmyonlkwd) = yhasdbprsd kdcsnunduz (aqbltvjmdg )
View more
Positive
05 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free